Abstract
AbstractAdding a new dimension to the body of research on COVID economics, this article considers the determinants of vaccine variety across nations. Driven by supply chain issues, development timelines, pricing, and vaccine nationalism, the number of available vaccines varies considerably across nations. Results show that greater pandemic severity and more populous nations had more vaccines, while nations with large land areas had fewer vaccines. Finally, while island nations were likely to have fewer vaccines, authoritarian regimes were mostly no different from other regimes. Greater COVID risks mostly lowered vaccine variety, as did supply chain issues and the prevalence of other infectious diseases. Finally, nations with worse institutional quality had more vaccines, ceteris paribus.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
